Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lu-DWJ155

Radiopharmaceutical · developed by Novartis Pharmaceuticals

Phase 1 Most advanced trial
NVS Developer

What is Lu-DWJ155?

Lu-DWJ155 is a lutetium-177 radiolabeled agent, [177Lu]Lu-DWJ155, studied in breast cancer, non-small cell lung cancer, gastric or gastroesophageal junction cancer, and bladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Radiopharmaceutical
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Bladder CancerBreast CancerGastric/Gastroesophageal Junction (GEJ) CancerNon-small Cell Lung Cancer (NSCLC)

More from Novartis Pharmaceuticals

Follow NVS, the company behind Lu-DWJ155

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.